ABSTRACT: Topiramate is a structurally novel anti-epileptic drug with at least 3 postulated mechanisms of action including: 1) potentiation of GABA responses, 2) impairment of AMPA/kainate glutamate receptors and 3) suppression of high frequency action potential firing. It has a favourable pharmacokinetic profile with rapid absorption, good bio-availability, linear pharmacokinetics, relatively long half-life and limited pharmacokinetic drug interactions. However, topiramate can reduce the estrogen component of oral contraceptive medications. Women may require birth control preparations containing 50 (Xg of estrogen. Topiramate clearance is reduced in severe renal failure and increased by enzyme-inducing antiepileptic drugs. The dose of topiramate may have to be reduced in renal failure or when withdrawing enzyme inducers. RESUME: Pharmacocinetique et pharmacodynamique du topiramate. Le topiramate est un medicament antiepileptique dont la structure est nouvelle et pour lequel on postule au moins trois mficanismes d'action dont: 1) la potentiation des r6ponses GABAergiques; 2) le blocage des recepteurs au AMPA/kainate glutamate et 3) la suppression de la decharge du potentiel d'action de haute frequence. II a un profil pharmacocinetique favorable avec une absorption rapide, une bonne biodisponibilit6, une pharmacocinetique lineaire, une demi-vie relativement longue et peu d'interactions pharmacocinetiques medicamenteuses. Cependant, le topiramate peut diminuer l'efficacite' des oestrogenes des contraceptifs oraux. Les femmes peuvent avoir besoin de contraceptifs oraux contenant 50 ug d'oestrogenes. La clairance du topiramate est diminu6e dans Pinsuffisance reriale severe et augmented par les antiepileptiques qui sont des inducteurs enzymatiques. La dose de topiramate doit etre diminu£e dans l'insuffisance renale ou quand on cesse un inducteur enzymatique.
Epileptic seizures can often be controlled with available drugs; however, at least 25-30% of patients continue to suffer from seizures or have intolerable side effects. Standard antiepileptic drugs (e.g., phenytoin, carbamazepine, barbiturates, sodium valproate) have pharmacokinetic properties which can produce complex drug interactions which limit their use. New drugs with novel mechanisms of action and more favourable pharmacokinetic profiles are needed in order to improve seizure control while minimizing side effects. This review will focus on the mechanisms of action and pharmacokinetics of topiramate which was introduced in Canada for treatment of epilepsy in 1997.
Topiramate (2,3:4,5-bis-0-(l-methylethylidene)-fi-D-fructopyranose sulfamate) has a novel chemical structure. It is a sulfamated derivative of fructose, a naturally occurring monosaccharide.
Mechanisms of Action
Topiramate has been shown to be effective in several animal models of epilepsy, including: maximal electroshock seizures in rats and mice; 1 tonic and absence seizures in spontaneous epileptic rats; clonic and tonic seizures in DBA mice; 2 stroke epilepsy in rats; 2 and kindled seizures in rats. 4 It elevates the seizure threshold but does not block the seizures induced by subcutaneous pentylenetetrazole. 1 These pre-clinical studies suggested that topiramate might have a broad spectrum of action against multiple seizure types including partial, generalized tonic-clonic seizures and perhaps absence.
The mechanisms of anticonvulsant action of topiramate are still not fully understood. Although its sulfamate group suggested that topiramate might be a carbonic anhydrase inhibitor, its effects on carbonic anhydrase are weak and not thought to be one of its major mechanisms of anti-convulsant action.
1 However, preliminary studies suggest that three potential mechanisms might contribute to the anti-convulsant effect.
Topiramate reversibly blocks sustained repetitive action potential firing in hippocampal pyramidal neurons. 5 The effect is similar to those of state-dependent sodium channel blockers, such as phenytoin and carbamazepine.
Topiramate has been shown to enhance chloride flux and to potentiate GABA A currents. 6 The mechanism of GABA A potentiation appears similar to that of benzodiazepines with an increase in the frequency of channel opening, but no increase in open time duration. 7 However, this action is not mediated through the benzodiazepine site on the GABA A channel since it was not inhibited by the benzodiazepine antagonist, flumazenil. Topiramate has been shown to reduce inward kainate-evoked 
Pharmacokinetics
Topiramate has a favourable pharmacokinetic profile ( Table  2) . It is rapidly absorbed with peak serum levels occurring 1-4 hours after an oral dose. 910 Bio-availability exceeds 80% following an oral dose and is not significantly affected by food. 10 Plasma concentrations are linearly related to dose. 10 Protein binding is negligible (9-17%)." The clearance of topiramate can be reduced in patients with severe renal impairment by up to 54%. 12 This can result in significant increases in plasma topiramate levels. When renal function is significantly impaired, the topiramate dose may have to be reduced. Topiramate is not extensively metabolized with 75-80% of the drug excreted unchanged in the urine 10 when given in monotherapy. Severe hepatic failure may result in moderate increases in plasma topiramate levels, however, these are usually not clinically significant. The elimination half-life is between 20-30 hours in the absence of enzyme-inducing agents 10 making it suitable for once or twice daily dosing schedule. However, enzyme inducers (e.g., phenytoin, carbamazepine or phenobarbital) can increase metabolism up to 50% and reduce the half- (Table 3) . However, the effects on phenytoin were not considered to be clinically significant. Topiramate has no significant effect on carbamazepine or valproate concentrations. Topiramate can reduce the plasma estrogen levels by up to 30% in women taking oral contraceptives 16 (Table 4) . Women should be warned of the potential for reduced efficacy of oral contraceptives and advised to either use alternative forms of contraception or be prescribed oral contraceptives containing higher estrogen content (e.g., 50 |0.g).
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There is limited experience with interactions with other medications. However, potential interactions have been explored using an in-vitro model with various human cytochrome P450 isoforms. 17 These results suggest that topiramate would have no inhibitory effects on neuroleptics, tricyclic anti-depressants, caffeine, theophylline or Coumadin.
Pharmacokinetic parameters in the elderly are similar to those in younger adults. Dosage adjustments in the elderly are generally not required unless there is significant renal impairment. 
Effect of Topiramate on drug concentration
increase -20% no effect ? no effect decrease.
